计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC 50 of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P) , and induces cell apoptosis . Anticancer activity
In Vitro
Ceranib-2 (10 nM-10 µM; 72 hours; SKOV3 cells) treatment inhibits cell proliferation and/or survival with an IC 50 value of 0.73 μM. Ceranib-2 (0.75-1.5 µM; 48 hours; SKOV3 cells) treatment causes accumulation of cells in the sub-G1 (apoptosis), G2 and S (0.75 μM only) phases of the cell cycle, concomitant with reductions in the number of cells in G1 phase. Ceranib-2 produces a dose-dependent decrease in ceramidase activity, with 50% inhibition at 28 μM, induces the accumulation of multiple ceramide species, and decreases levels of sphingosine and S1P. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: SKOV3 cells Concentration: 10 nM-10 µM Incubation Time: 72 hours Result: Cell proliferation and/or survival were inhibited with an IC 50 value of 0.73 μM for Ceranib-2. Cell Cycle AnalysisCell Line: SKOV3 cells Concentration: 0.75 μM, or 1.5 μM Incubation Time: 48 hours Result: Induced cell-cycle arrest and cell death.
In Vivo
Ceranib-2 (20-50 mg/kg; intraperitoneal injection; daily for 5 days per week; for 3 weeks; female Balb/c mice) treatment delays tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity . Intraperitoneal administration of 50 mg/kg Ceranib-2 results in progressive increases in its circulating levels, reaching a peak plasma concentration of approximately 40 μM at the 2 hr time point. Ceranib-2 appears to be cleared with a half-life of less than 2 hr . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Balb/c mice injected with JC murine mammary adenocarcinoma cells Dosage: 20 mg/kg or 50 mg/kg Administration: Intraperitoneal injection; daily for 5 days per week; for 3 weeks Result: Delayed tumor growth in a syngeneic tumor model.
Form:Solid
IC50& Target:IC50: 28 μM (Ceramidase)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 喹啉及其衍生物 |
| 亚类(Subclass) | 苯基喹啉 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯基喹啉 |
| 其他上位类(Alternative Parents) | 苯基吡啶 羟基肉桂酸及其衍生物 喹诺酮类及其衍生物 羟基喹啉 苯乙烯 芳基酮 羟基吡啶 1-羟基-2-未取代苯类化合物 乙烯基酸 杂芳族化合物 烯酮类 丙烯酰化合物 氮杂环化合物 有机光子化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1-羟基-2-未取代苯环化合物 - 4-苯基吡啶 - 丙烯酰基基团 - α,β-不饱和酮 - 芳香族杂多环化合物 - 芳基溴化物 - 氮杂环 - 苯基化合物 - 酮 - 杂芳香族化合物 - 烃衍生物 - 羟基肉桂酸或其衍生物 - 羟基吡啶 - 羟基喹啉 - 酮 - 单环苯基基团 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 苯酚 - 苯基吡啶 - 吡啶 - 喹啉酮 - 苯乙烯 - 乙烯基羧酸 |
| 描述(Description) | 该化合物属于苯基喹啉类有机化合物。这类杂环化合物含有被苯基取代的喹啉结构单元。 |
| 外部描述符(External Descriptors) | 暂无 |
H302: 吞食有害
H413: 可能对水生生物造成长期的有害影响
P264: 处理后要彻底洗手。
P270: 使用本产品时,请勿进食、饮水或吸烟。
P273: 避免释放到环境中。
P330: 漱口
P501: 将内容物/容器处理到。。。
P301+P317: 如果被吞咽:请寻求医疗帮助。